A Study of the Efficacy and Safety of DigiFab in Antepartum Subjects with Severe Preeclampsia

About this Study

This study will test the effect and safety of Digifab in pregnant women with severe preeclampsia.

Sponsor Protocol ID:2017-0110
IRB Number:2017-0110
Closed for Enrollment
Interventional
Early Phase 1
May 28, 2019
Eligibility Criteria
18 years old
Both Male and Female
No
No
No

Inclusion Criteria1. At least 18 years of age or older
2. Will be treated with expectant management
3. Willing and able to provide written informed consent

Exclusion Criteria

  1. Prior to randomization, the decision to induce or deliver the subject within 24 hours has been made
  2. Weight > 150 kg
  3. Eclampsia
  4. Significant antecedent obstetrical problems which may, in the opinion of the investigator, interfere with study assessments or safe participation in the study
  5. Evidence of non-reassuring fetal well-being
  6. Evidence of clinically significant fetal anomaly or known chromosomal abnormality
  7. Chronic renal disease
  8. Active hepatic disease, antiphospholipid antibody syndrome, or lupus
  9. Medical or psychiatric disorder which, in the opinion of the investigator, is unstable or which might interfere with study assessments or safe participation in the study.                                                                                                                                                                                  
  10. Estimated fetal weight 
  11. Any investigational drug use within 30 days of screen
  12. Planned interventional clinical study participation for infants
  13. Current history of methamphetamine or cocaine abuse

Categories Click category to view its trials.
Women's Health
Participating Locations
Wiser Hospital for Women and Infants - UMMC
Contact Information
Contact Name: Sheila Belk
Phone Number: 601-984-5377
Email: sbelk@umc.edu
Principal Investigator:Morris, Rachael F, M.D.
How to participate in our Clinical Trials